160663-56-9

Upstream product

• 160663-54-7 [6-Methoxy-2-(4-methoxyphenyl)benzo[b]furan-3-yl][4-methoxyphenyl]methanone 

Downstream Products

• 170847-48-0 2-(4-methoxyphenyl)-3-[4-[2-(hexamethyleneimin-1-yl)ethoxy]benzoyl]-6-methoxybenzofuran 
• 170847-42-4 [2-(4-methoxyphenyl)-6-methoxybenzofuran-3-yl][4-[2-diethylaminoethoxy]phenyl]methanone 
• 170847-38-8 [2-(4-Methoxyphenyl)-6-methoxybenzofuran-3-yl][4-(2-(1-piperidinyl)ethoxy]phenyl]methanone 
• 170847-44-6 [2-(4-methoxyphenyl)-6-methoxybenzofuran-3-yl][4-[2-diisopropylaminoethoxy]phenyl]methanone 

Relevant academic research and scientific papers

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods for treating resistant tumors

The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

Methods of treating nueropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

HETEROCYCLIC NEUROPEPTIDE Y RECEPTOR ANTAGONISTS

This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein. Another embodiment of this invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.